Professor John Gribben is the Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London, UK and Centre Lead for the Centre for Hemato-Oncology at Barts Cancer Institute. After doctoral studies at University College London as the recipient of a Leukaemia Research Fund and Welcome Trust Fellowships, in 1988 he was awarded a Fogarty Fellowship from NIH and MRC and he continued postdoctoral training and completed his Oncology Fellowship at Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass.  He was appointed to the faculty at Harvard Medical School and remained as Associate Professor of Medicine until returning to London in 2007. 

His primary research interests include the management of leukaemia and lymphoma, the identification of tumor antigens, and eradication of minimal residual disease and immunotherapy of cancer (including stem-cell transplantation and CAR-T therapy and the  impact of immune system and outcome following cancer treatment, how this can positively impact patients’ quality of life and on continuing to mentor the next generation of clinician scientists. At Barts NHS Trust he leads the Stem Cell Transplant and Immune Effector Cell Immunotherapy Program and is the JACIE License holder for the stem cell transplant  and immune effector cell program.  

He was President of European Hematology Association (EHA) from 2019-2021 and served on the Executive Board of EHA from 2015 to 2023 where he championed increased role of patient representation. He is a Fellow of the Royal College of Physicians and a Fellow of the Royal College of Pathology. He served as an Editor of Blood from 2007-2014. He was elected as a member of the American Society for Clinical Investigation in 2004 and elected as a Fellow of the Academy of Medical Science in UK in 2008.  He serves on the Board of Trustees of the London Clinic. He is Chair of the international workshop for NHL (iwNHL),  was co-Chair of the international workshop for CART (iwCART)  and a Board member of the international workshop for CLL (iwCLL).  He is an internationally recognized translational cancer researcher, and the author of 578 manuscripts and 72 books and book chapters. He was awarded the Binet-Rai Medal from iwCLL in 2017 for his outstanding contribution to research into Chronic Lymphocytic Leukaemia and the Jose Carreras Lifetime Achievement Award from the European Hematology Association in 2024 for his services to haematology research.